Koru Med Sys - KRMD STOCK NEWS

KORU Medical Systems has announced an agreement with a biopharmaceutical company to validate its FREEDOM Infusion System for use with a novel biologic drug. The drug developer is expected to begin Phase III studies by the end of 2023 for the treatment of a rare genetic disease. This collaboration adds to KORU Medical's existing partnerships for Phase II and Phase III studies of treatments in various medical fields.

KORU Medical Systems, Inc. has submitted a 510(k) premarket notification submission to the FDA for the use of its FREEDOM60® Infusion System with Hizentra® 50 mL prefilled syringes. The company aims to simplify subcutaneous therapy for patients and improve their quality of life. The submission is expected to reduce drug preparation tasks by up to 80% for patients using prefilled syringes with the FREEDOM™ Infusion System. The FDA approved the 50 mL Hizentra prefilled syringe in April 2023, making it the most prescribed subcutaneous immunoglobulin available in prefilled syringes.

KORU Medical Systems (NASDAQ: KRMD) has announced that it will report its first quarter 2023 financial results on May 4, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide updates on corporate developments. The call can be accessed by dialing (800)-734-8507 for U.S. participants, or (212)-231-2925 for international calls, using conference ID: 22026692. A live and archived webcast will also be available on the company’s website. KORU Medical focuses on innovative subcutaneous drug delivery systems designed to enhance patient quality of life, with products like the FREEDOM Syringe Infusion System.

KORU Medical Systems, Inc. (NASDAQ: KRMD) reported strong financial results for Q4 and the full year 2022, achieving a 13% increase in net revenue for Q4 to $7.3 million and 19% growth for the year, totaling $27.9 million. The company saw significant growth in its Novel Therapies business, with revenues skyrocketing 259.9% in Q4, thanks to new collaborations. Although the gross profit increased by 6.4%, it dropped as a percentage of revenue to 55.5% due to rising manufacturing costs. The company anticipates 2023 revenue between $32.5 million and $33.5 million, representing a 17-20% growth.

KORU Medical Systems (NASDAQ: KRMD) announced it will report its fourth quarter and full year 2022 financial results on March 8, 2023, at 4:30 p.m. ET. A conference call and webcast will follow to discuss the results and provide a corporate update. The company's product line includes the FREEDOM Syringe Infusion System, which supports patient home care with innovative drug delivery solutions. Investors can access the call by dialing the provided numbers for the U.S., Canada, and international callers, or via the archived webcast on the company’s website.

KORU Medical Systems, Inc. (NASDAQ: KRMD) has announced a development agreement with a pharmaceutical company to enhance its Freedom Infusion System for subcutaneous immunoglobulin therapy using prefilled syringes. This adaptation aims to facilitate home drug delivery for patients, as prefilled syringes are preferred for their ease of use. The Freedom Infusion System is the only approved system for this application. While the financial terms of the agreement remain undisclosed, the partnership is seen as a significant step towards expanding the number of FDA-approved therapies available for patients globally.

KORU Medical Systems (NASDAQ: KRMD), a medical technology company, announced its participation in two investor conferences on November 17, 2022. The management will present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum at 11:30 am EST, with a live and archived webcast available on their website. They will also attend the 13th Annual Craig-Hallum Alpha Select Conference on the same day. KORU Medical specializes in innovative subcutaneous drug delivery systems aimed at improving patient quality of life.